Heilongjiang ZBD Pharmaceutical Co Ltd (603567) — Capital Reinvestment Ratio
Heilongjiang ZBD Pharmaceutical Co Ltd (603567) has a Capital Reinvestment Ratio of 0.08x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥283.54 Million) in capital expenditures (CN¥21.27 Million). Check Heilongjiang ZBD Pharmaceutical Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Heilongjiang ZBD Pharmaceutical Co Ltd Capital Reinvestment Ratio (2011–2025)
This chart tracks Heilongjiang ZBD Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see Heilongjiang ZBD Pharmaceutical Co Ltd (603567) cash conversion ratio.
Annual Capital Reinvestment Ratio for Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2025)
Year-by-year Capital Reinvestment Ratio for Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2025. See Heilongjiang ZBD Pharmaceutical Co Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.21x | CN¥322.10 Million | CN¥68.52 Million | ▼ -81.5% |
| 2024 | 1.15x | CN¥164.31 Million | CN¥189.15 Million | ▼ -79.4% |
| 2020 | 5.60x | CN¥155.18 Million | CN¥868.65 Million | ▲ +591.7% |
| 2019 | 0.81x | CN¥220.92 Million | CN¥178.79 Million | ▼ -29.1% |
| 2018 | 1.14x | CN¥367.40 Million | CN¥419.59 Million | ▲ +97.9% |
| 2017 | 0.58x | CN¥853.19 Million | CN¥492.42 Million | ▼ -97.1% |
| 2016 | 20.14x | CN¥15.83 Million | CN¥318.74 Million | ▲ +9644.1% |
| 2014 | 0.21x | CN¥386.32 Million | CN¥79.85 Million | ▼ -78.6% |
| 2013 | 0.97x | CN¥174.68 Million | CN¥168.73 Million | ▼ -36.1% |
| 2012 | 1.51x | CN¥154.25 Million | CN¥233.09 Million | ▲ +13.2% |
| 2011 | 1.33x | CN¥104.71 Million | CN¥139.77 Million | — |